Literature DB >> 28530662

PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.

Gang Chen1,2, Yong Ho Kim1,3, Hui Li4, Hao Luo1,4, Da-Lu Liu1, Zhi-Jun Zhang1, Mark Lay1, Wonseok Chang1, Yu-Qiu Zhang4, Ru-Rong Ji1,4,5.   

Abstract

Programmed cell death ligand-1 (PD-L1) is typically produced by cancer cells and suppresses immunity through the receptor PD-1 expressed on T cells. However, the role of PD-L1 and PD-1 in regulating pain and neuronal function is unclear. Here we report that both melanoma and normal neural tissues including dorsal root ganglion (DRG) produce PD-L1 that can potently inhibit acute and chronic pain. Intraplantar injection of PD-L1 evoked analgesia in naive mice via PD-1, whereas PD-L1 neutralization or PD-1 blockade induced mechanical allodynia. Mice lacking Pd1 (Pdcd1) exhibited thermal and mechanical hypersensitivity. PD-1 activation in DRG nociceptive neurons by PD-L1 induced phosphorylation of the tyrosine phosphatase SHP-1, inhibited sodium channels and caused hyperpolarization through activation of TREK2 K+ channels. PD-L1 also potently suppressed nociceptive neuron excitability in human DRGs. Notably, blocking PD-L1 or PD-1 elicited spontaneous pain and allodynia in melanoma-bearing mice. Our findings identify a previously unrecognized role of PD-L1 as an endogenous pain inhibitor and a neuromodulator.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28530662      PMCID: PMC5831162          DOI: 10.1038/nn.4571

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  50 in total

1.  TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain.

Authors:  Cristian Acosta; Laiche Djouhri; Roger Watkins; Carol Berry; Kirsty Bromage; Sally N Lawson
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

2.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

Review 3.  Pain regulation by non-neuronal cells and inflammation.

Authors:  Ru-Rong Ji; Alexander Chamessian; Yu-Qiu Zhang
Journal:  Science       Date:  2016-11-04       Impact factor: 47.728

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.

Authors:  Juan Miguel Jimenez-Andrade; Joseph R Ghilardi; Gabriela Castañeda-Corral; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2011-09-09       Impact factor: 6.961

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  SHANK3 Deficiency Impairs Heat Hyperalgesia and TRPV1 Signaling in Primary Sensory Neurons.

Authors:  Qingjian Han; Yong Ho Kim; Xiaoming Wang; Di Liu; Zhi-Jun Zhang; Alexandra L Bey; Mark Lay; Wonseok Chang; Temugin Berta; Yan Zhang; Yong-Hui Jiang; Ru-Rong Ji
Journal:  Neuron       Date:  2016-12-01       Impact factor: 17.173

8.  SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

Authors:  Michael Hebeisen; Lukas Baitsch; Danilo Presotto; Petra Baumgaertner; Pedro Romero; Olivier Michielin; Daniel E Speiser; Nathalie Rufer
Journal:  J Clin Invest       Date:  2013-02-08       Impact factor: 14.808

Review 9.  Bone cancer pain: causes, consequences, and therapeutic opportunities.

Authors:  Patrick Mantyh
Journal:  Pain       Date:  2013-07-31       Impact factor: 6.961

10.  Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain.

Authors:  Matthias Schweizerhof; Sebastian Stösser; Martina Kurejova; Christian Njoo; Vijayan Gangadharan; Nitin Agarwal; Martin Schmelz; Kiran Kumar Bali; Christoph W Michalski; Stefan Brugger; Anthony Dickenson; Donald A Simone; Rohini Kuner
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440

View more
  54 in total

1.  Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates.

Authors:  Zilong Wang; Changyu Jiang; Qianru He; Megumi Matsuda; Qingjian Han; Kaiyuan Wang; Sangsu Bang; Huiping Ding; Mei-Chuan Ko; Ru-Rong Ji
Journal:  Sci Transl Med       Date:  2020-02-19       Impact factor: 17.956

Review 2.  Neuroimmunity and chronic pain.

Authors:  J Royds; C McCrory
Journal:  BJA Educ       Date:  2018-10-26

3.  A checkpoint to pain.

Authors:  Michael Hirth; Jagadeesh Gandla; Rohini Kuner
Journal:  Nat Neurosci       Date:  2017-06-27       Impact factor: 24.884

4.  Modulation of PDCD1 exon 3 splicing.

Authors:  Junjie Sun; Jialin Bai; Tao Jiang; Yuan Gao; Yimin Hua
Journal:  RNA Biol       Date:  2019-08-28       Impact factor: 4.652

Review 5.  Neuroimmune modulation of pain and regenerative pain medicine.

Authors:  Thomas Buchheit; Yul Huh; William Maixner; Jianguo Cheng; Ru-Rong Ji
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

6.  Recent Progress in Understanding the Mechanisms of Pain and Itch: the Second Special Issue.

Authors:  Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2018-01-16       Impact factor: 5.203

7.  Chronic Methadone Use Alters the CD8+ T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli.

Authors:  Claire Mazahery; Bryan L Benson; Angélica Cruz-Lebrón; Alan D Levine
Journal:  J Immunol       Date:  2020-01-22       Impact factor: 5.422

8.  GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain.

Authors:  Sangsu Bang; Ya-Kai Xie; Zhi-Jun Zhang; Zilong Wang; Zhen-Zhong Xu; Ru-Rong Ji
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

9.  Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Authors:  Michalis Mastri; Christina R Lee; Amanda Tracz; Robert S Kerbel; Melissa Dolan; Yuhao Shi; John M L Ebos
Journal:  Mol Cancer Ther       Date:  2018-04-25       Impact factor: 6.261

10.  Peripheral Nerve Resident Macrophages and Schwann Cells Mediate Cancer-Induced Pain.

Authors:  Francesco De Logu; Matilde Marini; Lorenzo Landini; Daniel Souza Monteiro de Araujo; Niccolò Bartalucci; Gabriela Trevisan; Gennaro Bruno; Martina Marangoni; Brian L Schmidt; Nigel W Bunnett; Pierangelo Geppetti; Romina Nassini
Journal:  Cancer Res       Date:  2021-03-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.